July 9, 2020
The US FDA has rejected Eisai’s and US Merck’s accelerated approval bid for their Lenvima (lenvatinib)-Keytruda (pembrolizumab) combination therapy in first-line liver cancer, apparently due to its nod given to Roche’s rival combo regimen in late May. The two partners...read more